Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 5, 2020

Approval of Novartis’ ofatumumab delayed by FDA review extension

By Victoria Smith

Review of ofatumumab, Novartis’ multiple sclerosis drug (MS), has been extended by the US Food and Drug Administration (FDA) until September 2020, originally expected to occur this month.

Ofatumumab is a fully-humanised anti-CD20 monoclonal antibody (mAb) currently indicated under the brand name Arzerra as therapy for refractory chronic lymphocytic leukaemia (CLL). The drug is expected to enter the US MS market next year, as well as in the five major European markets of France, Germany, Italy, Spain and the UK, and Japan, in 2022. Read more here.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU